首页> 美国卫生研究院文献>Translational Psychiatry >Failure to extinguish fear and genetic variability in the human cannabinoid receptor 1
【2h】

Failure to extinguish fear and genetic variability in the human cannabinoid receptor 1

机译:无法消除人类大麻素受体1的恐惧和遗传变异

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Failure to extinguish fear can lead to persevering anxiety and has been postulated as an important mechanism in the pathogenesis of human anxiety disorders. In animals, it is well documented that the endogenous cannabinoid system has a pivotal role in the successful extinction of fear, most importantly through the cannabinoid receptor 1. However, no human studies have reported a translation of this preclinical evidence yet. Healthy medication-free human subjects (N=150) underwent a fear conditioning and extinction procedure in a virtual reality environment. Fear potentiation of the eyeblink startle reflex was measured to assess fear-conditioned responding, and subjective fear ratings were collected. Participants were genotyped for two polymorphisms located within the promoter region (rs2180619) and the coding region (rs1049353) of cannabinoid receptor 1. As predicted from the preclinical literature, acquisition and expression of conditioned fear did not differ between genotypes. Crucially, whereas both homozygote (G/G, N=23) and heterozygote (A/G, N=68) G-allele carriers of rs2180619 displayed robust extinction of fear, extinction of fear-potentiated startle was absent in A/A homozygotes (N=51). Additionally, this resistance to extinguish fear left A/A carriers of rs2180619 with significantly higher levels of fear-potentiated startle at the end of the extinction training. No effects of rs1049353 genotype were observed regarding fear acquisition and extinction. These results suggest for the first time involvement of the human endocannabinoid system in fear extinction. Implications are that genetic variability in this system may underlie individual differences in anxiety, rendering cannabinoid receptor 1 a potential target for novel pharmacological treatments of anxiety disorders.
机译:无法消除恐惧会导致持续的焦虑感,并被认为是人类焦虑症发病机理中的重要机制。在动物中,有充分的文献证明,内源性大麻素系统在成功消除恐惧中起着关键作用,最重要的是通过大麻素受体1。但是,尚无人类研究报道这种临床前证据的翻译。健康无药的人类受试者(N = 150)在虚拟现实环境中进行了恐惧条件的调节和灭绝程序。测量眨眼惊吓反射的恐惧增强以评估恐惧条件反应,并收集主观恐惧等级。对参加者进行了基因型分型,分析了大麻素受体1的启动子区域(rs2180619)和编码区域(rs1049353)内的两个多态性。根据临床前文献的预测,条件恐惧感的获得和表达在基因型之间没有差异。至关重要的是,rs2180619的纯合子(G / G,N = 23)和杂合子(A / G,N = 68)G等位基因携带者均表现出对恐惧的强烈消灭,而在A / A纯合子中则没有恐惧增强的惊吓消灭。 (N = 51)。此外,这种消灭恐惧的抵抗力使rs2180619的A / A携带者在消灭训练结束时会产生明显更高的恐惧增强惊吓。没有观察到rs1049353基因型对恐惧获得和消亡的影响。这些结果首次表明人类内源性大麻素系统参与了恐惧的消除。这意味着该系统的遗传变异可能是焦虑个体差异的基础,使大麻素受体1成为焦虑症新型药物治疗的潜在靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号